Today, Cambridge Heart, the developer of remarkable, non-invasive diagnostic tests for cardiac disease and especially those at risk for sudden cardiac arrest (SCA), reported that the company’s Microvolt T-Wave Alternans™ (MTWA) test product was approved by Japan’s Ministry of Health, Labor, and Welfare (MHLW) for reimbursement coverage, opening up commercial opportunities within Japan’s huge healthcare market.
Patients considered at risk for lethal arrhythmias, history of heart attack, cardiomyopathy, Brugada syndrome, and the like can now rest a little easier knowing that Japan’s MHLW has them covered for this crucial testing solver that has proven effective in predicting life-threatening arrhythmias.
The company’s proprietary Micro-V Alternans Sensors™ are generally used in a typical stress test type scenario (in hospital, physician’s office, or outpatient clinic) and constitute a proven test system developed on CAMH’s proprietary Analytic Spectral Method®, which analyzes the electrocardiogram (ECG), focusing on the alternating pattern in the T-wave portion of the surface ECG to detect subtle wave form anomalies not visible to the naked eye. Several studies have validated the clinical efficacy of the MTWA test in detecting cases of potential arrhythmic death and the fundamental technology behind the MTWA test (originally based on research conducted at MIT) represents a serious life-saving advantage
President and CEO of CAMH, Ali Haghighi-Mood, underscored the tremendous potential for the product line in Japan’s robust, advanced, and tech-savvy healthcare market. Haghighi-Mood called the reimbursement coverage decision by Japan’s MHLW a real milestone for the company’s important MTWA technology and a key index of the global potential of the offering.
Indeed, the ability to offer an underserved global market a real weapon in the struggle to manage at-risk patient SCA susceptibility, in-and-of-itself is significant. The radical potential for uptake possible via shrewd execution of the partner strategy with Fukuda Denshi should be readily apparent and the swelling senior population in Japan is a huge market, for whom the reimbursement decision means a great deal.
Professor of Medicine at Japan’s renowned Toho University Medical Center, Dr. Takanori Ikeda, emphasized the large body of clinical evidence supporting MTWA testing’s predictive value for patients at risk of life-threatening arrhythmias and expressed how pleased the organization was about the reimbursement decision. Dr. Takanori Ikeda also explained that the ability to use the test more broadly, combined with the gradual, stepped method uses in testing (as opposed to the dangerously intense method in regular stress testing), opens up the testing protocol to a larger user base.
Additionally, because MTWA testing can be conducted via use of pharmacologic agents, instead of pacing to obtain the requisite data, the true span of cases where MTWA could see use is even greater. The company even offers MTWA testing and report interpretation multimedia programs/training in order to facilitate roll out of the technology.
For more information on this important reimbursement coverage decision, or to stay abreast of the latest developments at Cambridge Heart, Inc., please visit the company’s website at www.CambridgeHeart.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment